1. Anti-ceramide single-chain variable fragment mitigates radiation GI syndrome mortality independent of DNA repair.
- Author
-
Rotolo JA, Fong CS, Bodo S, Nagesh PK, Fuller J, Sharma T, Piersigilli A, Zhang Z, Fuks Z, Singh VK, and Kolesnick R
- Subjects
- Acute Radiation Syndrome mortality, Animals, DNA Repair, Gastrointestinal Diseases mortality, Humans, Injections, Subcutaneous, Intestine, Small pathology, Jurkat Cells drug effects, Jurkat Cells radiation effects, Mice, Single-Chain Antibodies therapeutic use, Acute Radiation Syndrome drug therapy, Ceramides immunology, Gastrointestinal Diseases drug therapy, Intestine, Small drug effects, Intestine, Small radiation effects, Single-Chain Antibodies pharmacology
- Abstract
After 9/11, threat of nuclear attack on American urban centers prompted government agencies to develop medical radiation countermeasures to mitigate hematopoietic acute radiation syndrome (H-ARS) and higher-dose gastrointestinal acute radiation syndrome (GI-ARS) lethality. While repurposing leukemia drugs that enhance bone marrow repopulation successfully treats H-ARS in preclinical models, no mitigator potentially deliverable under mass casualty conditions preserves GI tract. Here, we report generation of an anti-ceramide 6B5 single-chain variable fragment (scFv) and show that s.c. 6B5 scFv delivery at 24 hours after a 90% lethal GI-ARS dose of 15 Gy mitigated mouse lethality, despite administration after DNA repair was complete. We defined an alternate target to DNA repair, an evolving pattern of ceramide-mediated endothelial apoptosis after radiation, which when disrupted by 6B5 scFv, initiates a durable program of tissue repair, permitting crypt, organ, and mouse survival. We posit that successful preclinical development will render anti-ceramide 6B5 scFv a candidate for inclusion in the Strategic National Stockpile for distribution after a radiation catastrophe.
- Published
- 2021
- Full Text
- View/download PDF